|
|
Clinical Trials & Registries
Experience
UBC scientists and clinical operations teams have supported hundreds of prescription and over-the-counter medicines, enrolled over 220,000 patients in clinical trials, and managed over 50,000 study sites. Our scientists have designed almost 3,000 clinical protocols, implemented over 350 clinical trials, and executed over 2,500 health outcomes studies.
To view a representative selection of our recent clinical development and safety programs, click on the areas listed below:
|
Project / Study
Description
|
Development
Phase
|
Study Centers
|
Patients
Enrolled
|
|
Sinusitis /
Allergy
|
II
|
10
|
50
|
|
Sinusitis /
Allergy
|
III/IV
|
20
|
80
|
|
Seasonal Rhinitis
|
IV
|
300
|
3,000
|
|
Pediatric
Bronchitis
|
IV
|
2,200
|
11,500
|
|
Project / Study
Description
|
Development
Phase
|
Study Centers
|
Patients
Enrolled
|
|
Pain - Narcotic
Antagonist
|
II
|
1
|
75
|
|
Acute
Epicondylitis
|
III
|
20
|
200
|
|
Chronic Pain-Topical
Narcotic Analgesic
|
III
|
2
|
60
|
|
Acute Cancer Pain - Narcotic
Analgesic
|
III
|
20
|
150
|
|
Acute Cancer Pain - Narcotic
Analgesic
|
III
|
4
|
100
|
|
Acute Cancer Pain - Narcotic
Analgesic
|
III
|
20
|
170
|
|
Post-Operative
Pain
|
III
|
2
|
150
|
|
Pre-Induction
Sedative
|
III
|
10
|
200
|
|
Dental Pain
|
III
|
5
|
125
|
|
Pain - Facial Laser
Resurfacing
|
III
|
3
|
50
|
|
Pain - Facial Dermal Filler
Injections
|
III
|
2
|
70
|
|
Pain - Facial Vascular
Lesion Removal
|
III
|
3
|
80
|
|
Pain - Tattoo
Removal
|
III
|
3
|
60
|
|
Pain - Anesthetic
Duration
|
III
|
1
|
20
|
|
Pain - Dermal
Procedures
|
III
|
8
|
370
|
|
Pain - Pediatric Vascular
Access
|
III
|
4
|
80
|
|
Pain - Pediatric Dermal
Procedures
|
III
|
8
|
80
|
|
Osteoarthritis
|
III/IV
|
33
|
400
|
|
Osteoarthritis in African
American patients
|
III/IV
|
24
|
300
|
|
Osteoarthritis in Asian
patients
|
III/IV
|
40
|
300
|
|
Osteoarthritis in Hispanic
patients
|
III/IV
|
25
|
300
|
|
Non-responders to NSAIDs in
Osteoarthritis
|
IV
|
80
|
740
|
|
Post-surgical
Analgesia
|
IV
|
8
|
180
|
|
Post-surgical
Analgesia
|
IV
|
10
|
180
|
|
Carpel Tunnel
|
IV
|
1
|
40
|
|
Knee Pain
|
IV
|
1
|
15
|
|
Chronic Pain (Athletic
Injury)
|
IV
|
8
|
120
|
|
Post-Menopausal &
Corticosteroid-induced osteoporosis*
|
IV
|
5,000
|
25,000
|
|
Pain - Carpal Tunnel
Syndrome
|
IV
|
2
|
100
|
*
Indicates large, streamlined Phase IV
study
|
Project / Study
Description
|
Development
Phase
|
Study Centers
|
Patients
Enrolled
|
|
Hypertension
(pharmacokinetics)
|
II
|
1
|
24
|
|
Hypertension
|
II
|
1
|
12
|
|
Iron Overload
|
II
|
3
|
45
|
|
b-Thalassemia
|
II
|
2
|
21
|
|
Non-insulin Dependent
Diabetes
|
II
|
20
|
600
|
|
Critical Arrhythmias -
Pediatrics
|
III
|
33
|
60
|
|
Pediatric Hypertension
(pharmacokinetics)
|
III
|
5
|
20
|
|
Blood Coagulation
|
III
|
2
|
50
|
|
Hypertension
|
III
|
20
|
360
|
|
Hypertension /
Angina
|
III
|
200
|
400
|
|
Hypertension
|
III
|
120
|
250
|
|
Reinfarcation
Management
|
III
|
33
|
300
|
|
Non-insulin Dependent
Diabetes
|
III
|
40
|
200
|
|
Hypertension
|
IV
|
1,500
|
5,200
|
|
Pediatric
Hypertension
|
IV
|
24
|
120
|
|
Hypertension
|
IV
|
1,700
|
5,000
|
|
Hypertension
|
IV
|
2,000
|
5,000
|
|
Hypertension
|
IV
|
22
|
420
|
|
Hypertension*
|
IV
|
1,500
|
7,000
|
|
Hypertension
|
IV
|
120
|
1,200
|
|
Hypertension*
|
IV
|
6,000
|
30,000
|
|
Hypertension*
|
IV
|
3,000
|
15,000
|
|
Hypertension /
Angina*
|
IV
|
1,500
|
5,200
|
|
Hypertension*
|
IV
|
1,000
|
3,000
|
|
Congestive Heart
Failure*
|
IV
|
2,150
|
7,900
|
| Hyperlipidemia/Hypercholesterolemia* |
IV
|
2,000
|
6,000
|
|
b-Thalassemia and
Diamond Blackfan
Anaemia
|
IV
|
1
|
15
|
|
Non-insulin Dependent
Diabetes
|
IV
|
2,000
|
6,500
|
|
Diabetes diagnostic
device
|
IV
|
5,000
|
20,000
|
|
Diabetes*
|
IV
|
1,450
|
7,000
|
|
Hyperglycemia*
|
IV
|
20
|
600
|
*
Indicates large, streamlined Phase IV
study
|
Project / Study
Description
|
Development
Phase
|
Study Centers
|
Patients
Enrolled
|
|
Epilepsy (pharmacy
management)
|
II
|
42
|
300
|
|
Migraine (H.M.O.
based)
|
II
|
1
|
135
|
|
Narcolepsy (sleep lab
based)
|
II
|
1
|
20
|
|
Depression
|
II
|
2
|
60
|
|
Social Phobia
(office-based)
|
II
|
1
|
20
|
|
Parkinson's Disease
(hospital based)
|
II
|
2
|
60
|
| Smoke cessation |
II |
9 |
541 |
|
Pediatric
Depression
|
III
|
20
|
240
|
|
Pediatric
Depression
|
III
|
50
|
400
|
|
Pediatric
Depression
|
III
|
30
|
300
|
|
Epilepsy
|
III
|
30
|
210
|
|
Schizophrenia /
Schizo-Affective Disorder
|
III
|
86
|
550
|
|
Schizophrenia
|
III
|
43
|
360
|
|
Schizophrenia /
Schizo-Affective Disorder
|
III
|
45
|
360
|
|
Generalized Anxiety
Disorder
|
III
|
15
|
225
|
|
Epilepsy
|
III
|
60
|
400
|
|
Anxiety
|
III
|
15
|
225
|
|
Migraine*
|
III
|
64
|
1,200
|
|
Migraine
|
III
|
18
|
125
|
|
Epilepsy
|
III/IV
|
40
|
300
|
|
Pediatric Relapsing-Remiting
MS (retrospective)
|
IV
|
5
|
30
|
|
Migraine*
|
IV
|
700
|
2,500
|
|
Pediatric ADHD*
|
IV
|
750
|
1,200
|
|
Migraine
|
IV
|
20
|
150
|
|
Migraine
|
IV
|
771
|
3,020
|
|
Epilepsy*
|
IV
|
3,000
|
5,000
|
|
Migraine (hospital- and
office-based)
|
IV
|
18
|
225
|
|
Migraine (H.M.O.
based)
|
IV
|
1
|
135
|
|
Adult ADHD*
|
IV
|
500
|
5,000
|
*
Indicates large, streamlined Phase IV
study
|
Project / Study
Description
|
Development
Phase
|
Study Centers
|
Patients
Enrolled
|
|
Therapeutic Interchange of
Anticoagulants
|
--
|
1
|
100
|
|
Therapeutic Interchange of
Anticoagulants
|
--
|
1
|
60
|
|
Hypersensitive
Patients
|
II
|
10
|
60
|
|
Dosage Calculation Pharmacy
Service
|
IIIb
|
8
|
--
|
|
Generalized Seizure
Epilepsy
|
IIIb
|
70
|
104
|
|
Project / Study
Description
|
Development
Phase
|
Study Centers
|
Patients
Enrolled
|
|
Psoriasis
|
Ib/IIa
|
1
|
30
|
|
Acne
|
III
|
30
|
200
|
|
Burn/Wound
|
III
|
20
|
200
|
|
Psoriasis
|
Ib/IIa
|
1
|
60
|
|
Project / Study
Description
|
Development
Phase
|
Study Centers
|
Patients
Enrolled
|
|
Irritable Bowel
Syndrome
|
II/III
|
40
|
700
|
|
NSAID Users without a
History of Ulcers
|
III
|
60
|
200
|
|
Erosive
Esophagitis
|
III
|
64
|
700
|
|
Continued Treatment of
NSAID-Induced Ulcers
|
III
|
60
|
120
|
|
Duodenal Ulcers
|
III
|
60
|
200
|
|
Gastric Ulcers
|
III
|
60
|
200
|
|
Gastroenterology
|
III
|
35
|
500
|
|
H. Pylori
- Duodenal Ulcer
|
III
|
15
|
180
|
|
Small Bowel
Lesions
|
IV
|
15
|
300
|
|
NSAID-Induced
Ulcers
|
IV
|
60
|
200
|
|
Gastroenterology
|
IV
|
60
|
600
|
|
NSAID Use and Gastroduodenal
Ulcers
|
IV
|
50
|
605
|
|
Project / Study
Description
|
Development
Phase
|
Study Centers
|
Patients
Enrolled
|
|
Infections in Bone Marrow
Transplant
|
III
|
8
|
120
|
|
Fungal Infections in
Patients with Neutropenia
|
III
|
6
|
125
|
|
Urinary Tract
Infections
|
III
|
10
|
400
|
|
Upper Respiratory
Infections
|
III
|
10
|
400
|
|
Gynecology - STD
(hospital-based)
|
III
|
75
|
1,400
|
|
Neonatal Respiratory
Distress
|
III
|
15
|
500
|
|
HIV+ (hospital- and
office-based)
|
III
|
43
|
100
|
|
Antifungal agent in HIV+
patients (hospital based)
|
III
|
6
|
140
|
|
Chronic
Bronchitis
|
IV
|
2,000
|
7,000
|
|
Bronchitis, Sinusitis,
Community Acquired Pneumonia*
|
IV
|
5,500
|
18,400
|
|
Bronchitis*
|
IV
|
2,200
|
10,000
|
|
Pediatric Otitis
Media*
|
IV
|
6,000
|
28,500
|
|
Uncomplicated Urinary Tract
Infection*
|
IV
|
3,200
|
8,000
|
|
HIV+*
|
IV
|
27
|
100
|
*
Indicates large, streamlined Phase IV
study
|
Project / Study
Description
|
Development
Phase
|
Study Centers
|
Patients
Enrolled
|
|
Cutaneous T-Cell
Lymphoma
|
I
|
9
|
12
|
|
B Cell ALL
Leukemia
|
I
|
5
|
20
|
|
Refractory Hematologic
Malignancies
|
I
|
5
|
14
|
|
Advanced T-Cell
Leukemia
|
II
|
50
|
20
|
|
Prophylaxis in Bone Marrow
Transplant Patients with Neutropenia
|
II
|
6
|
140
|
|
Prophylaxis in Bone Marrow
Transplant Patients with Neutropenia
|
II
|
5
|
120
|
|
Cutaneous T Cell
Lymphoma
|
II
|
20
|
45
|
|
Renal Cell
Carcinoma
|
III
|
1
|
100
|
|
Anti-Emetic
Compounds
|
III
|
1
|
20
|
|
Non-Small Cell Lung
Cancer
|
IV
|
36
|
160
|
| Location |
Physicians |
Patients |
| United States |
15,000 |
45,000 |
| Canada |
1,000 |
5,000 |
| United Kingdom |
1,000 |
6,000 |
|
Project / Study
Description
|
Development
Phase
|
Study Centers
|
Patients
Enrolled
|
|
Overactive
Bladder
|
IIIb
|
250
|
2,000
|
|
Overactive
Bladder
|
IIIb
|
40
|
360
|
|
Erectile
Dysfunction*
|
IV
|
7,500
|
30,000
|
|
Overactive
Bladder*
|
IV
|
167
|
700
|
|
Overactive
Bladder*
|
IV
|
178
|
600
|
|
Urinary
Incontinence
|
IV
|
40
|
400
|
|
Testosterone Replacement
Therapy*
|
IV
|
200
|
1,000
|
|
Urinary
Incontinence*
|
IV
|
350
|
1,000
|
|
Overactive
Bladder*
|
IV
|
1,500
|
4,000
|
*
Indicates large, streamlined Phase IV
study
|
